Iovance Biotherapeutics, Inc. (NASDAQ: IOVA)

This lawsuit is for anyone who acquired securities in Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) from May 9, 2024 through May 8, 2025.

The lawsuit alleges that the Company and certain of its executives violated federal law. Specifically, the lawsuit alleges that, throughout the time period mentioned above, the Company misled investors regarding its financial condition. More specifically, the lawsuit alleges that the Company misled investors by failing to timely update guidance.

On May 8, 2025, Iovance released its first quarter 2025 financial results, revealing a quarterly total product revenue of $49.3 million, a significant decline from the prior quarter’s $73.7 million. The Company also announced its full fiscal year 2025 total product revenue guidance had been slashed from $450 million – $475 million to $250 million – $300 million, a reduction of over 40% at the midpoint. The Company stated it was “revising full-year 2025 revenue guidance to reflect recent launch dynamics” of the Company’s T cell immunotherapy, Amtagvi^® (lifileucel). Amtagvi was commercially launched in the U.S. in the first half of 2024. On this news, the price of the Company’s stock dropped precipitously on unusually heavy trading volume.

The Law Offices of Howard G. Smith seeks to recover damages on behalf of class members. If you acquired securities in Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) prior to from May 9, 2024 through May 8, 2025 you may join the lawsuit by submitting your information online, or you may call the Law Offices of Howard G. Smith and speak to Mr. Smith directly to learn how he can protect your rights.